WAM
BHVN

Wolverine Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Wolverine Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,465
Closed -$1.52M – 2897
2022
Q2 		$1.52M Buy
+10,465
New +$1.34M 0.02% 635
2020
Q3 		– Sell
-27
Closed -$1K – 1980
2020
Q2 		$1K Buy
+27
New +$1.44K ﹤0.01% 1512

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wolverine Asset Management's BHVN Position: Q3 2022 in Review

Wolverine Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 10,465 shares — an estimated $1.52M sold.

Wolverine Asset Management first reported a position in BHVN in Q2 2020 and held it in 2 quarters. The position peaked at $1.52M in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Wolverine Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Wolverine Asset Management sold 10,465 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $1.52M.
  • Wolverine Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 2 quarters.
  • Wolverine Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.52M in Q2 2022.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Wolverine Asset Management's 13F filing for Q3 2022, filed 10 Nov 2022.